meta|Evidence - COVID-19
click on circles to display study description...
hydroxychloroquine (n=214) vs. placebo (n=227)
randomized controlled trial some concerns about risk of bias
Hydroxychloroquine
Hydroxychloroquine loading dose of 800 mg at the time of randomization and then 400 mg in daily doses at 8:00 AM for 9 days.
Placebo
Corresponding tablets of inert material (talc). Placebo bottles were matched for the same number of tablets as active lopinavir-ritonavir.
3 arms: Hydroxychloroquine, lopinavir-ritonavir or placebo (1:1:1).
COVID 19 outpatients
Patients 18 years or older; reported less than 8 days since onset of flulike symptoms or chest computerized tomography scan consistent with COVID-19 and at least one additional criterion for high risk: aged 50 years or older; presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, or emphysema; diabetes requiring oralmedication or insulin; hypertension requiring treatment; known cardiovascular diseases (congestive heart failure of any etiology, documented coronary artery disease, clinically manifest miscellaneous heart disease); symptomatic lung disease on chronic treatment; history of transplantation; obesity (body mass index 30 [calculated as weight in kilograms divided by height in meters squared]); immunocompromised status due to disease (eg, those living with HIV with a CD4 T-cell count of <200 cells/mm3, confirmed malignant neoplasm); immunocompromised status due to medication (eg, people taking 10 mg or more of prednisone equivalents a day); and patients with cancer.
Double-blind.
10 cities in Brazil.
The trial was stopped after the interim analysis for futility with a sample size of 685 patients.
hydroxychloroquine (n=689) vs. placebo (n=683)
randomized controlled trial some concerns about risk of bias
hydroxychloroquine 400 mg BID in the first day, 400 mg OD thereafter for a total of seven days
placebo
COVID 19 outpatients
double-blind
56 Brazilian sites
hydroxychloroquine (n=244) vs. placebo (n=247)
randomized controlled trial some concerns about risk of bias
hydroxychloroquine 600mg
oral hydroxychloroquine, 800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days
placebo
COVID 19 outpatients
double-blind
United States and Canada (40 states and 3 provinces)
hydroxychloroquine (n=-9) vs. placebo (n=-9)
randomized controlled trial risk of bias NA
hydroxychloroquine
600mg daily for 7 days
placebo
COVID 19 outpatients
double blind
1 center, germany
found in Axfors et al meta-analysis
hydroxychloroquine (n=152) vs. placebo (n=152)
randomized controlled trial risk of bias NA
hydroxychloroquine
(600 mg daily for one week)
placebo
arms: placebo, oral HC, or oral HC plus oral AZ
COVID 19 outpatients
double-blind
2 centres, Quatar
hydroxychloroquine (n=15) vs. standard of care (n=13)
randomized controlled trial some concerns about risk of bias
hydroxychloroquine
2x200mg twice a day
placebo
COVID 19 outpatients
double-blind
1 centre, USA
interim analysis. study discontinuated due to rapide decline of infection rate during the study accrual period.
hydroxychloroquine (n=137) vs. standard of care (n=157)
randomized controlled trial some concerns about risk of bias
hydroxychloroquine 400mg
hydroxychloroquine (800 mg on day 1, followed by 400 mg once daily for 6 days)
standard of care
COVID 19 outpatients
moste patients were healthcare workesr (86.7%)
open-label
Catalonia, Spain
powered by vis.js Network